Research programme: anticancer therapeutics - Theramex
Alternative Names: TX DLatest Information Update: 08 Feb 2018
Price :
$50 *
At a glance
- Originator Theramex SAM
- Class
- Mechanism of Action Estrogen receptor antagonists; Sulfatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 01 Feb 2018 Teva Women's Health was sold by Teva Pharmaceuticals to CVC Capital Partners, to create an international pharmaceutical company dedicated to Women’s Health named Theramex
- 08 Sep 2004 Preclinical trials in Breast cancer in Monaco (unspecified route)